Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
AstraZeneca
McKesson
Johnson and Johnson
McKinsey

Last Updated: January 17, 2020

DrugPatentWatch Database Preview

REBIF Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Recent Litigation for REBIF

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Amgen Inc. v. Accord Healthcare, Inc.2018-06-28
Idenix Pharmaceuticals LLC v. Gilead Sciences, Inc.2014-07-01
Abbott Laboratories v. Watson Laboratories Inc. - Florida2010-01-22

See all REBIF litigation

Pharmacology for REBIF

Patent Text Search: US Patents for REBIF

These patents were identified by searching patent claims

International Patents for REBIF

Supplementary Protection Certificates for REBIF

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2016/052 Ireland   Start Trial PRODUCT NAME: DACLIZUMAB; REGISTRATION NO/DATE: EU/1/16/1107 20160701
93353 Luxembourg   Start Trial PRODUCT NAME: COBICISTAT OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI ET ATAZANAVIR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, EN PARTICULIER LE SULFATE D'ATAZANAVIR; AUTHORISATION NUMBER AND DATE: EU/1/15/1025
300859 Netherlands   Start Trial PRODUCT NAME: COBICISTAT, DAN WEL EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN ATAZANAVIR, DAN WEL EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, IN HET BIJZONDER ATAZANAVIRSULFAAT; REGISTRATION NO/DATE: EU/1/15/1025 20150715
2017002 Norway   Start Trial PRODUCT NAME: KOBICISTAT ELLER FARMASOEYTISK; REG. NO/DATE: EU/1/15/1025 20150810
313 5027-2016 Slovakia   Start Trial PRODUCT NAME: DAKLIZUMAB; REGISTRATION NO/DATE: EU/1/16/1107 20160705
122016000098 Germany   Start Trial PRODUCT NAME: DACLIZUMAB; REGISTRATION NO/DATE: EU/1/16/1107 20160701
CA 2017 00003 Denmark   Start Trial PRODUCT NAME: COBICISTAT ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF OG ATAZANAVIR ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER ATAZANAVIRSULFAT; REG. NO/DATE: EU/1/15/1025/001-002 20150715
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Dow
Boehringer Ingelheim
Harvard Business School
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.